Ocugen Stock Quote OCGN - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

1.63

Bid

1.62

Ask

1.63

Volume

13,437,004

1.33 Day's Range 1.65

0.345 52 Week Range 2.105

Market Cap

420.664M

Previous Close

1.33

Open

1.34

Last Trade

1.63

Last Trade Time

Financial Volume

$ 20,699,775

VWAP

1.5405

Average Volume (3m)

10,288,151

Shares Outstanding

256,502,434

Dividend Yield

PE Ratio

-6.67

Earnings Per Share (EPS)

-0.25

Revenue

6.04M

Net Profit

-63.08M

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Ortho,prosth,surg Appl,suply

Website

ocugen.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

Ocugen Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker OCGN. The last closing price for Ocugen was $1.33. Over the last year, Ocugen shares have traded in a share price range of $ 0.345 to $ 2.105.

Ocugen currently has 256,502,434 shares outstanding. The market capitalization of Ocugen is $420.66 million. Ocugen has a price to earnings ratio (PE ratio) of -6.67.

Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results

MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress

MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...

Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024

MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting

MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.37	29.3650793651	1.26	1.65	1.2505	5464000	1.35431321	CS
4	-0.38	-18.9054726368	2.01	2.08	1.11	7128605	1.49000621	CS
12	1.08	196.363636364	0.55	2.105	0.55	10288151	1.32859222	CS
26	1.2382	316.028586013	0.3918	2.105	0.351	6149172	1.15307217	CS
52	0.92	129.577464789	0.71	2.105	0.345	5521278	0.87335018	CS
156	-7.98	-83.0385015609	9.61	17.65	0.345	11568642	5.75996585	CS
260	-1.61	-49.6913580247	3.24	18.77	0.17	17789239	5.48075271	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NUVOHoldco Nuvo Group DG Ltd	$ 5.2108 (155.43%)	43.44M
XBPXBP Europe Holdings Inc	$ 3.4999 (65.09%)	55.73M
PLTNPlutoniam Acquisition Corporation	$ 9.40 (56.41%)	1.43M
PRFTPerficient Inc	$ 73.27 (52.30%)	11.68M
NRXPNRX Pharmaceuticals Inc	$ 3.05 (45.24%)	9.31M
LYRALyra Therapeutics Inc	$ 0.519 (-87.12%)	108.65M
GLYCGlycoMimetics Inc	$ 0.3165 (-82.70%)	40.92M
EYPTEyePoint Pharmaceuticals Inc	$ 11.15 (-43.52%)	9.65M
LGHLWLion Group Holding Ltd	$ 0.0047 (-32.86%)	100.74k
MMATMeta Materials Inc	$ 2.44 (-27.16%)	580.58k
LYRALyra Therapeutics Inc	$ 0.519 (-87.12%)	108.65M
SQQQProShares UltraPro Short QQQ	$ 10.70 (-3.43%)	94.71M
NKLANikola Corporation	$ 0.6497 (-1.19%)	89.11M
MARAMarathon Digital Holdings Inc	$ 20.695 (18.12%)	87.05M
TSLATesla Inc	$ 184.76 (1.97%)	84.41M